American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
Tóm tắt
Từ khóa
Tài liệu tham khảo
Mechanick, 2010, American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update, Endocr Pract., 16, 270, 10.4158/EP.16.2.270
Mechanick, 2014, American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists--2014 Update and the AACE G4G Program, Endocr Pract., 20, 692, 10.4158/EP14166.PS
Mechanick, 2004, American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines, Endocr Pract., 10, 353, 10.4158/EP.10.4.353
Wright, 2014, The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine, J Bone Miner Res., 29, 2520, 10.1002/jbmr.2269
Burge, 2007, Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025, J Bone Miner Res., 22, 465, 10.1359/jbmr.061113
Singer, 2015, Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States, Mayo Clin Proc., 90, 53, 10.1016/j.mayocp.2014.09.011
Looker, 1997, Prevalence of low femoral bone density in older U.S. adults from NHANES III, J Bone Miner Res., 12, 1761, 10.1359/jbmr.1997.12.11.1761
Faulkner, 1999, Discordance in patient classification using T-scores, J Clin Densitom., 2, 343, 10.1385/JCD:2:3:343
Melton, 1993, Prevalence and incidence of vertebral deformities, Osteoporos Int., 3, 113, 10.1007/BF01623271
Siris, 2014, The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group, Osteoporos Int., 25, 1439, 10.1007/s00198-014-2655-z
Leslie, 2012, High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice, Osteoporos Int., 23, 391, 10.1007/s00198-011-1592-3
Siris, 2012, What’s in a name? What constitutes the clinical diagnosis of osteoporosis?, Osteoporos Int., 23, 2093, 10.1007/s00198-012-1991-0
Guglielmi, 2011, Integrated imaging approach to osteoporosis: state-of-the-art review and update, Radiographics., 31, 1343, 10.1148/rg.315105712
Wainwright, 2005, Hip fracture in women without osteoporosis, J Clin Endocrinol Metab., 90, 2787, 10.1210/jc.2004-1568
Nayak, 2010, Health Beliefs about Osteoporosis and Osteoporosis Screening in Older Women and Men, Health Educ J., 69, 267, 10.1177/0017896910364570
Nelson, 2010, Screening for osteoporosis: an update for the U.S. Preventive Services Task Force, Ann Intern Med., 153, 99, 10.7326/0003-4819-153-2-201007200-00262
Hiligsmann, 2010, Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence, Value Health., 13, 394, 10.1111/j.1524-4733.2009.00687.x
Thompson, 2010, Screening for falls and osteoporosis: prevention practice for the hand therapist, J Hand Ther., 23, 212, 10.1016/j.jht.2009.11.001
Barr, 2010, Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk, Osteoporos Int., 21, 561, 10.1007/s00198-009-1007-x
Kanis, 2007
Gallagher, 2010, Bone: Is screening for secondary causes of osteoporosis worthwhile?, Nat Rev Endocrinol., 6, 360, 10.1038/nrendo.2010.86
Orwig, 2006, Hip fracture and its consequences: differences between men and women, Orthop Clin North Am., 37, 611, 10.1016/j.ocl.2006.08.003
Kanis, 2011, Interpretation and use of FRAX in clinical practice, Osteoporos Int., 22, 2395, 10.1007/s00198-011-1713-z
Lewiecki, 2011, FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference, J Clin Densitom., 14, 223, 10.1016/j.jocd.2011.05.018
Kanis, 2014, Epidemiology and Quality of Life Working Group of IOF. Worldwide uptake of FRAX., Arch Osteoporos., 9, 166, 10.1007/s11657-013-0166-8
Kanis, 2012, FRAX(®) with and without bone mineral density, Calcif Tissue Int., 90, 1, 10.1007/s00223-011-9544-7
Hillier, 2011, WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?, J Bone Miner Res., 26, 1774, 10.1002/jbmr.372
Silverman, 2010, The utility and limitations of FRAX: A US perspective, Curr Osteoporos Rep., 8, 192, 10.1007/s11914-010-0032-1
van den Bergh, 2010, Assessment of individual fracture risk: FRAX and beyond, Curr Osteoporos Rep., 8, 131, 10.1007/s11914-010-0022-3
Kreidieh, 2014, Impact of changes in mortality on FRAX-derived fracture probabilities, Bone., 62, 43, 10.1016/j.bone.2014.01.014
Kanis, 2011, Guidance for the adjustment of FRAX according to the dose of glucocorticoids, Osteoporos Int., 22, 809, 10.1007/s00198-010-1524-7
Leslie, 2011, Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement, Osteoporos Int., 22, 839, 10.1007/s00198-010-1461-5
Leslie, 2012, Does osteoporosis therapy invalidate FRAX for fracture prediction?, J Bone Miner Res., 27, 1243, 10.1002/jbmr.1582
Sambrook, 2007, Influence of fall related factors and bone strength on fracture risk in the frail elderly, Osteoporos Int., 18, 603, 10.1007/s00198-006-0290-z
Kanis, 2007, The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, Osteoporos Int., 18, 1033, 10.1007/s00198-007-0343-y
2015
Johnell, 2005, Predictive value of BMD for hip and other fractures, J Bone Miner Res., 20, 1185, 10.1359/JBMR.050304
Stone, 2003, BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures, J Bone Miner Res., 18, 1947, 10.1359/jbmr.2003.18.11.1947
Cummings, 1993, Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group, Lancet., 341, 72, 10.1016/0140-6736(93)92555-8
Marshall, 1996, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ., 312, 1254, 10.1136/bmj.312.7041.1254
Austin, 2012, Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, J Bone Miner Res., 27, 687, 10.1002/jbmr.1472
Barzel, 2003, Recommended testing in patients with low bone density, J Clin Endocrinol Metab., 88, 1404, 10.1210/jc.2002-021660
Tannenbaum, 2002, Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women, J Clin Endocrinol Metab., 87, 4431, 10.1210/jc.2002-020275
Lindsay, 2001, Risk of new vertebral fracture in the year following a fracture, JAMA., 285, 320, 10.1001/jama.285.3.320
Gehlbach, 2012, Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women, J Bone Miner Res., 27, 645, 10.1002/jbmr.1476
Edwards, 2007, Prior fractures are common in patients with subsequent hip fractures, Clin Orthop Relat Res., 461, 226, 10.1097/BLO.0b013e3180534269
Camacho, 2008, Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis, J Clin Oncol., 26, 5380, 10.1200/JCO.2008.17.7451
Lane, 2001, An update on glucocorticoid-induced osteoporosis, Rheum Dis Clin North Am., 27, 235, 10.1016/S0889-857X(05)70196-4
Lewiecki, 2006, Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry, J Clin Endocrinol Metab., 91, 4215, 10.1210/jc.2006-1178
Greenspan, 2001, Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis, J Clin Densitom., 4, 373, 10.1385/JCD:4:4:373
Schousboe, 2006, Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice, Osteoporos Int., 17, 281, 10.1007/s00198-005-2010-5
Binkley, 2005, Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures, Osteoporos Int., 16, 1513, 10.1007/s00198-005-1891-7
Siminoski, 2005, Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures, Osteoporos Int., 16, 403, 10.1007/s00198-004-1709-z
Siminoski, 2006, The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women, Osteoporos Int., 17, 290, 10.1007/s00198-005-2017-y
Chesnut, 1997, Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density, Am J Med., 102, 29, 10.1016/S0002-9343(96)00387-7
Ross, 1998, Rapid bone loss is associated with increased levels of biochemical markers, J Bone Miner Res., 13, 297, 10.1359/jbmr.1998.13.2.297
Garnero, 1999, Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study, J Bone Miner Res., 14, 1614, 10.1359/jbmr.1999.14.9.1614
Garnero, 1996, Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study, J Bone Miner Res., 11, 1531, 10.1002/jbmr.5650111021
Garnero, 2000, Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study, J Bone Miner Res., 15, 1526, 10.1359/jbmr.2000.15.8.1526
Eastell, 2003, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate, J Bone Miner Res., 18, 1051, 10.1359/jbmr.2003.18.6.1051
Vasikaran, 2011, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards, Osteoporos Int., 22, 391, 10.1007/s00198-010-1501-1
Bauer, 2012, National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges, Osteoporos Int., 23, 2425, 10.1007/s00198-012-2049-z
Bauer, 2006, Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis, J Clin Endocrinol Metab., 91, 1370, 10.1210/jc.2005-1712
Hochberg, 2002, Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents, J Clin Endocrinol Metab., 87, 1586, 10.1210/jcem.87.4.8415
Bauer, 2014, Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study, JAMA Int Med., 174, 1126, 10.1001/jamainternmed.2014.1232
Eastell, 2011, Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence, J Bone Miner Res., 26, 1662, 10.1002/jbmr.342
Delmas, 2009, Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis, J Bone Min Res., 24, 1544, 10.1359/jbmr.090310
Eastell, 2011, Effects of denosumab on bone turnover markers in postmenopausal osteoporosis, J Bone Miner Res., 26, 530, 10.1002/jbmr.251
Carmel, 2012, The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml, Osteoporos Int., 23, 2479, 10.1007/s00198-011-1868-7
Bischoff-Ferrari, 2004, Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults, Am J Med., 116, 634, 10.1016/j.amjmed.2003.12.029
Ross, 2011, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know, T.J Clin Endocrinol Metab., 96, 53, 10.1210/jc.2010-2704
Holick, 2011, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab., 96, 1911, 10.1210/jc.2011-0385
Holick, 2005, Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy, J Clin Endocrinol Metab., 90, 3215, 10.1210/jc.2004-2364
LeBoff, 2008, Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures, Osteoporos Int., 19, 1283, 10.1007/s00198-008-0582-6
Wimalawansa, 2012, Vitamin D in the new millennium, Curr Osteoporos Rep., 10, 4, 10.1007/s11914-011-0094-8
Baron, 2015, A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas, N Engl J Med., 373, 1519, 10.1056/NEJMoa1500409
Arora, 2015, Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial, Circulation., 131, 254, 10.1161/CIRCULATIONAHA.114.011732
Mason, 2014, Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial, Am J Clin Nutr., 99, 1015, 10.3945/ajcn.113.073734
Ng, 2014, Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial, Am J Clin Nutr., 99, 587, 10.3945/ajcn.113.067777
Knutsen, 2014, Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway, J Clin Endocrinol Metab., 99, 194, 10.1210/jc.2013-2647
Chaney, 2015, Effectiveness and Outcomes of Current Practice in Treating Vitamin D Deficiency in Patients Listed for Liver Transplantation, Endocr Pract., 21, 761, 10.4158/EP14416.OR
Farahati, 2015, Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany, Endocr Pract., 21, 122, 10.4158/EP14320.OR
Li, 2015, Vitamin D, parathyroid hormone, and heart failure in a chinese elderly population, Endocr Pract., 21, 30, 10.4158/EP14123.OR
Chapuy, 1997, Prevalence of vitamin D insufficiency in an adult normal population, Osteoporos Int., 7, 439, 10.1007/s001980050030
Boonen, 2007, Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials, J Clin Endocrinol Metab., 92, 1415, 10.1210/jc.2006-1404
Hansen, 2015, Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial, JAMA Int Med., 175, 1612, 10.1001/jamainternmed.2015.3874
Bischoff-Ferrari, 2005, Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials, JAMA., 293, 2257, 10.1001/jama.293.18.2257
Jackson, 2006, Calcium plus vitamin D supplementation and the risk of fractures, N Engl J Med., 354, 669, 10.1056/NEJMoa055218
Bischoff-Ferrari, 2004, Effect of Vitamin D on falls: a meta-analysis, JAMA., 291, 1999, 10.1001/jama.291.16.1999
Bischoff-Ferrari, 2006, Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?, Osteoporos Int., 17, 656, 10.1007/s00198-005-0030-9
Pfeifer, 2000, Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women, J Bone Miner Res., 15, 1113, 10.1359/jbmr.2000.15.6.1113
Autier, 2007, Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials, Arch Intern Med., 167, 1730, 10.1001/archinte.167.16.1730
Kearns, 2014, Large, single-dose, oral vitamin d supplementation in adult populations: a systematic review, Endocr Pract., 20, 341, 10.4158/EP13265.RA
Weaver, 2016, Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation, Osteoporos Int., 27, 367, 10.1007/s00198-015-3386-5
Porthouse, 2005, Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care, BMJ., 330, 1003, 10.1136/bmj.330.7498.1003
Shea, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis, Endocr Rev., 23, 552, 10.1210/er.2001-7002
Grant, 2005, Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial, Lancet., 365, 1621, 10.1016/S0140-6736(05)63013-9
Michaelsson, 2013, Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study, BMJ., 346, f228, 10.1136/bmj.f228
Bolland, 2011, Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis, BMJ., 342, d2040, 10.1136/bmj.d2040
Bolland, 2010, Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis, BMJ., 341, c3691, 10.1136/bmj.c3691
Bolland, 2008, Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial, BMJ., 336, 262, 10.1136/bmj.39440.525752.BE
Bostick, 1999, Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women, Am J Epidemiol., 149, 151, 10.1093/oxfordjournals.aje.a009781
Zhu, 2008, Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency, J Bone Miner Res., 23, 1343, 10.1359/jbmr.080327
Zhu, 2008, Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial, J Clin Endocrinol Metab., 93, 743, 10.1210/jc.2007-1466
Langsetmo, 2013, Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos), J Clin Endocrinol Metab., 98, 3010, 10.1210/jc.2013-1516
Bauer, 2013, Clinical practice. Calcium supplements and fracture prevention, N Engl J Med., 369, 1537, 10.1056/NEJMcp1210380
Prentice, 2013, Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study, Osteoporos Int., 24, 567, 10.1007/s00198-012-2224-2
Bolland, 2011, Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set, Am J Clin Nutr., 94, 1144, 10.3945/ajcn.111.015032
Moyer, 2013, U.S. Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 158, 691
Ross, 2011, The 2011 report on dietary reference intakes for calcium and vitamin D, Public Health Nutr., 14, 938, 10.1017/S1368980011000565
Alaimo, 1994, Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91, Adv Data., 1
Kim, 2014, Effect of water-soluble silicon supplementation on bone status and balance of calcium and magnesium in male mice, Biol Trace Elem Res., 158, 238, 10.1007/s12011-014-9936-4
Spencer, 1994, Effect of magnesium on the intestinal absorption of calcium in man, J Am Coll Nutr., 13, 485, 10.1080/07315724.1994.10718439
Braam, 2003, Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age, Calcif Tissue Int., 73, 21, 10.1007/s00223-002-2084-4
Alexandersen, 2001, Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial, JAMA., 285, 1482, 10.1001/jama.285.11.1482
Atkinson, 2004, The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial, Am J Clin Nutr., 79, 326, 10.1093/ajcn/79.2.326
Gallagher, 2004, The effect of soy protein isolate on bone metabolism, Menopause., 11, 290, 10.1097/01.GME.0000097845.95550.71
Hallström, 2006, Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women, Osteoporos Int., 17, 1055, 10.1007/s00198-006-0109-y
Kiel, 1990, Caffeine and the risk of hip fracture: the Framingham Study, Am J Epidemiol., 132, 675, 10.1093/oxfordjournals.aje.a115709
Barrett-Connor, 1994, Coffee-associated osteoporosis offset by daily milk consumption, The Rancho Bernardo Study, JAMA., 271, 280, 10.1001/jama.1994.03510280042030
Rizzoli, 2001, Protein intake and bone disorders in the elderly, Joint Bone Spine., 68, 383, 10.1016/S1297-319X(01)00295-0
Schurch, 1998, Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial, Ann Intern Med., 128, 801, 10.7326/0003-4819-128-10-199805150-00002
Kanis, 2005, Alcohol intake as a risk factor for fracture, Osteoporos Int., 16, 737, 10.1007/s00198-004-1734-y
Giampietro, 2010, The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort, Osteoporos Int., 21, 467, 10.1007/s00198-009-0981-3
Daniell, 1976, Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity, Arch Intern Med., 136, 298, 10.1001/archinte.1976.03630030032007
Kanis, 2005, Smoking and fracture risk: a meta-analysis, Osteoporos Int., 16, 155, 10.1007/s00198-004-1640-3
Kelley, 2002, Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data, J Gerontol A Biol Sci Med Sci., 57, M599, 10.1093/gerona/57.9.M599
Gardner, 2002, Application of a falls prevention program for older people to primary health care practice, Prev Med., 34, 546, 10.1006/pmed.2002.1017
Robertson, 2002, Preventing injuries in older people by preventing falls: a meta-analysis of individual-level data, J Am Geriatr Soc., 50, 905, 10.1046/j.1532-5415.2002.50218.x
Wolff, 1999, The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women, Osteoporos Int., 9, 1, 10.1007/s001980050109
Choi, 2012, Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis, J Am Med Dir Assoc, 13, e113
Sherrington, 2008, Effective exercise for the prevention of falls: a systematic review and meta-analysis, J Am Geriatr Soc., 56, 2234, 10.1111/j.1532-5415.2008.02014.x
Kelley, 2012, Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trials, BMC Musculoskelet Disord., 13, 177, 10.1186/1471-2474-13-177
Scott, 2010
Gillespie, 2012, Interventions for preventing falls in older people living in the community, Cochrane Database Syst Rev., 9
Granacher, 2013, The importance of trunk muscle strength for balance, functional performance, and fall prevention in seniors: a systematic review, Sports Med., 43, 627, 10.1007/s40279-013-0041-1
Tinetti, 1988, Risk factors for falls among elderly persons living in the community, N Engl J Med., 319, 1701, 10.1056/NEJM198812293192604
Hausdorff, 2001, Gait variability and fall risk in community-living older adults: a 1-year prospective study, Arch Phys Med Rehabil., 82, 1050, 10.1053/apmr.2001.24893
Stevens, 2006, Fatalities and injuries from falls among older adults-United States, 1993-2003 and 2001-2005, MMWR Morb Mortal Wkly Rep., 55, 1221
da Silva, 2010, Predictors of falls in women with and without osteoporosis, J Orthop Sports Phys Ther., 40, 582, 10.2519/jospt.2010.3239
Blain, 2014, Usefulness of bone density measurement in fallers, Joint Bone Spine., 5, 403, 10.1016/j.jbspin.2014.01.020
Briot, 2012, 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, Joint Bone Spine., 79, 304, 10.1016/j.jbspin.2012.02.014
van Doorn, 2003, Dementia as a risk factor for falls and fall injuries among nursing home residents, J Am Geriatr Soc., 51, 1213, 10.1046/j.1532-5415.2003.51404.x
Goodwin, 2014, Multiple component interventions for preventing falls and fall-related injuries among older people: systematic review and meta-analysis, BMC Geriatr., 14, 15, 10.1186/1471-2318-14-15
Kemmler, 2013, Effects of exercise on fracture reduction in older adults: a systematic review and meta-analysis, Osteoporos Int., 24, 1937, 10.1007/s00198-012-2248-7
Bischoff-Ferrari, 2009, Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials, BMJ., 339, b3692, 10.1136/bmj.b3692
Uusi-Rasi, 2015, Exercise and vitamin D in fall prevention among older women: a randomized clinical trial, JAMA Int Med., 175, 703, 10.1001/jamainternmed.2015.0225
Sanders, 2010, Annual high-dose oral vitamin D and falls and fractures in older women, JAMA., 303, 1815, 10.1001/jama.2010.594
Parker, 2006, Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review, BMJ., 332, 571, 10.1136/bmj.38753.375324.7C
Sawka, 2005, Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials, Osteoporos Int., 16, 1461, 10.1007/s00198-005-1932-2
Singh, 2004, Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents, J Rheumatol., 31, 1607
van Schoor, 2003, The Amsterdam Hip Protector Study: compliance and determinants of compliance, Osteoporos Int., 14, 353, 10.1007/s00198-003-1382-7
Warnke, 2004, Predictors of adherence to the use of hip protectors in nursing home residents, J Am Geriatr Soc., 52, 340, 10.1111/j.1532-5415.2004.52103.x
Kiel, 2007, Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial, JAMA., 298, 413, 10.1001/jama.298.4.413
Santesso, 2014, Hip protectors for preventing hip fractures in older people, Cochrane Database Syst Rev., 3
Gillespie, 2010, Hip protectors for preventing hip fractures in older people., Cochrane Database Syst Rev., 10.1002/14651858.CD001255.pub4
Wei, 2014, Effect of whole body vibration therapy on circulating serotonin levels in an ovariectomized rat model of osteoporosis, Iran J Basic Med Sci., 17, 62
Totosy de Zepetnek, 2009, Whole-body vibration as potential intervention for people with low bone mineral density and osteoporosis: a review, J Rehabil Res Dev, 46, 529, 10.1682/JRRD.2008.09.0136
Ruan, 2008, Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis, Chinese Med J (Engl), 121, 1155, 10.1097/00029330-200807010-00001
Li, 2009, Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis, Clin Rehabil., 23, 888, 10.1177/0269215509339002
Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Fracture Intervention Trial Research Group. Lancet., 348, 1535
Chesnut, 2004, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res., 19, 1241, 10.1359/JBMR.040325
Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group, JAMA., 282, 1344, 10.1001/jama.282.14.1344
Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporos Int., 11, 83, 10.1007/s001980050010
Kanis, 2005, Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture, Osteoporos Int., 16, 475, 10.1007/s00198-004-1698-y
Chesnut, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group, Am J Med., 109, 267, 10.1016/S0002-9343(00)00490-3
Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA., 282, 637, 10.1001/jama.282.7.637
Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med., 361, 756, 10.1056/NEJMoa0809493
Neer, 2001, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med., 344, 1434, 10.1056/NEJM200105103441904
Lyles, 2007, Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture, N Engl J Med, 357, 10.1056/NEJMoa074941
Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group, J Clin Endocrinol Metab., 85, 4118, 10.1210/jcem.85.11.6953
Black, 2006, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial, JAMA., 296, 2927, 10.1001/jama.296.24.2927
Bone, 2004, Ten years’ experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med., 350, 1189, 10.1056/NEJMoa030897
Miller, 2005, Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study, J Bone Miner Res., 20, 1315, 10.1359/JBMR.050313
Reginster, 2006, Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study, Ann Rheum Dis., 65, 654, 10.1136/ard.2005.044958
Eisman, 2008, Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study, J Rheumatol., 35, 488
McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group, N Engl J Med., 344, 333, 10.1056/NEJM200102013440503
Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med., 356, 1809, 10.1056/NEJMoa067312
Sorensen, 2003, Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience, Bone., 32, 120, 10.1016/S8756-3282(02)00946-8
Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial, JAMA., 288, 321, 10.1001/jama.288.3.321
Dawson-Hughes, 2008, Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA, Osteoporos Int., 19, 449, 10.1007/s00198-008-0559-5
Kanis, 2010, The effects of a FRAX revision for the USA, Osteoporos Int., 21, 35, 10.1007/s00198-009-1033-8
Ettinger, 2010, Updated fracture incidence rates for the US version of FRAX, Osteoporos Int., 21, 25, 10.1007/s00198-009-1032-9
Tosteson, 2008, Cost-effective osteoporosis treatment thresholds: the United States perspective, Osteoporos Int., 19, 437, 10.1007/s00198-007-0550-6
Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial, JAMA., 280, 2077, 10.1001/jama.280.24.2077
Watts, 2012, Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?, Osteoporos Int., 23, 327, 10.1007/s00198-011-1755-2
Bone, 2008, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women, J Clin Endocrinol Metab., 93, 2149, 10.1210/jc.2007-2814
Miller, 2008, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone., 43, 222, 10.1016/j.bone.2008.04.007
McClung, 2013, Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial, Osteoporos Int., 24, 227, 10.1007/s00198-012-2052-4
Bone, 2013, The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension, J Clin Endocrinol Metab., 98, 4483, 10.1210/jc.2013-1597
Watts, 2009, Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment, J Bone Miner Res., 24, 1125, 10.1359/jbmr.081256
McClung, 2004, Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis, J Bone Miner Res., 19, 11, 10.1359/jbmr.0301202
2015, Atelvia (risedronate sodium) delayed-release tablets In
Disease, 2009, Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney Intl Suppl, S1
Jones, 2002, Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions, Br J Haematol., 119, 576, 10.1046/j.1365-2141.2002.03835_4.x
Chang, 2003, Renal failure with the use of zoledronic acid, N Engl J Med., 349, 1676, 10.1056/NEJM200310233491721
Tarassoff, 2003, Renal failure with the use of zoledronic acid, N Engl J Med., 349, 1678
Adami, 1987, The acute-phase response after bisphosphonate administration, Calcif Tissue Int., 41, 326, 10.1007/BF02556671
Wysowski, 2005, Alendronate and risedronate: reports of severe bone, joint, and muscle pain, Arch Intern Med., 165, 346
Cardwell, 2010, Exposure to oral bisphosphonates and risk of esophageal cancer, JAMA., 304, 657, 10.1001/jama.2010.1098
Green, 2010, Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort, BMJ., 341, c4444, 10.1136/bmj.c4444
McClung, 2013, Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday, Am J Med., 126, 13, 10.1016/j.amjmed.2012.06.023
2014
2011, Evista (raloxifene hydrochloride) Tablet for Oral Use [package insert].
Delmas, 1997, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, N Engl J Med., 337, 1641, 10.1056/NEJM199712043372301
Siris, 2005, Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study, J Bone Miner Res., 20, 1514, 10.1359/JBMR.050509
Vogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial, JAMA., 295, 2727, 10.1001/jama.295.23.joc60074
Barrett-Connor, 2006, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, N Engl J Med., 355, 125, 10.1056/NEJMoa062462
2014, Fortical (calcitonin-salmon [rDNA origin]) Nasal Spray for intranasal use [package insert]
2014, Miacalcin (calcitonin-salmon) for injection and nasal spray [package insert]
Pun, 1989, Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures, Clin Ther., 11, 205
Ofluoglu, 2007, The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain, Clin Rheumatol., 26, 44, 10.1007/s10067-006-0228-z
Laroche, 2006, Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study, Clin Rheumatol., 25, 683, 10.1007/s10067-005-0159-0
Lyritis, 1999, Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study, Clin J Pain., 15, 284, 10.1097/00002508-199912000-00004
Lyritis, 1997, Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study, Acta Orthop Scand Suppl., 275, 112, 10.1080/17453674.1997.11744761
2014, 2014 Premarin (conjugated estrogens) Tablets, USP for oral use [package insert]
Pinkerton, 2014, Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial, J Clin Endocrinol Metab., 99, E189, 10.1210/jc.2013-1707
Cauley, 2003, Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial, JAMA., 290, 1729, 10.1001/jama.290.13.1729
Jackson, 2006, Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial, J Bone Miner Res., 21, 817, 10.1359/jbmr.060312
2012, Forteo (teriparatide [rDNA origin] injection) for subcutaneous use [package insert]
Vahle, 2002, Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety, Toxicol Pathol., 30, 312, 10.1080/01926230252929882
Vahle, 2004, Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose, Toxicol Pathol., 32, 426, 10.1080/01926230490462138
Subbiah, 2010, Of mice and men: divergent risks of teriparatide-induced osteosarcoma, Osteoporos Int., 21, 1041, 10.1007/s00198-009-1004-0
Lindsay, 2004, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis, Arch Intern Med., 164, 2024, 10.1001/archinte.164.18.2024
Black, 2005, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis, N Engl J Med., 353, 555, 10.1056/NEJMoa050336
Reginster, 2014, Cardiac concerns associated with strontium ranelate, Expert Opin Drug Saf., 13, 1209, 10.1517/14740338.2014.939169
2013, European Medicines Agency
Audran, 2013, A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years, Rheumatol Int., 33, 2231, 10.1007/s00296-012-2594-y
Cooper, 2014, 2014 Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD, Osteoporos Int., 25, 737, 10.1007/s00198-013-2582-4
Abrahamsen, 2014, Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate, Osteoporos Int., 25, 757, 10.1007/s00198-013-2469-4
Svanström, 2014, Use of strontium ranelate and risk of acute coronary syndrome: cohort study, Ann Rheum Dis., 73, 1037, 10.1136/annrheumdis-2014-205283
Blake, 2007, The correction of BMD measurements for bone strontium content, J Clin Densitom., 10, 259, 10.1016/j.jocd.2007.03.102
Greenspan, 1994, Femoral bone loss progresses with age: a longitudinal study in women over age 65, J Bone Miner Res., 9, 1959, 10.1002/jbmr.5650091216
Finkelstein, 2008, Bone mineral density changes during the menopause transition in a multiethnic cohort of women, J Clin Endocrinol Metab., 93, 861, 10.1210/jc.2007-1876
Gourlay, 2012, Bone-density testing interval and transition to osteoporosis in older women, N Engl J Med., 366, 225, 10.1056/NEJMoa1107142
Lewiecki, 2008, Assessing response to osteoporosis therapy, Osteoporos Int., 19, 1363, 10.1007/s00198-008-0661-8
Lewiecki, 2002, How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis?, J Bone Miner Res., 17, S367
Lenchik, 2002, What is the role of serial bone mineral density measurements in patient management?, J Clin Densitom., 5, S29, 10.1385/JCD:5:3S:S29
Baim, 2005, Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry, J Clin Densitom., 8, 371, 10.1385/JCD:8:4:371
Bouxsein, 2003, Mechanisms of osteoporosis therapy: a bone strength perspective, Clin Cornerstone, S13, 10.1016/S1098-3597(03)90043-3
Tosteson, 2003, Early discontinuation of treatment for osteoporosis, Am J Med., 115, 209, 10.1016/S0002-9343(03)00362-0
Shen, 2011, Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials, PLoS One., 6, 10.1371/journal.pone.0026267
Simon, 2013, Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture, Menopause., 20, 130, 10.1097/GME.0b013e318267f909
Schousboe, 2008, Vertebral Fracture Assessment: the 2007 ISCD Official Positions, J Clin Densitom., 11, 92, 10.1016/j.jocd.2007.12.008
Schousboe, 2013, Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry, J Clin Densitom., 16, 455, 10.1016/j.jocd.2013.08.004
Hochberg, 1999, Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group, Arthritis Rheum., 42, 1246, 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U
Watts, 2004, Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk, J Clin Densitom., 7, 255, 10.1385/JCD:7:3:255
Chapurlat, 2005, Risk of fracture among women who lose bone density during treatment with alendronate, The Fracture Intervention Trial, Osteoporos Int., 16, 842, 10.1007/s00198-004-1770-7
Ryg, 2009, Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001, J Bone Miner Res., 24, 1299, 10.1359/jbmr.090207
Black, 1999, Prevalent vertebral deformities predict hip fractures and new vertebral fractures but not wrist fractures, J Bone Miner Res., 14, 821, 10.1359/jbmr.1999.14.5.821
Gallagher, 2005, Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures, J Clin Endocrinol Metab., 90, 1583, 10.1210/jc.2004-0826
Lewiecki, 2013, Treat-to-target for osteoporosis: Is now the time?, J Clin Endocrinol Metab., 98, 946, 10.1210/jc.2012-3680
Cummings, 2013, Goal-directed treatment of osteoporosis, J Bone Miner Res., 28, 433, 10.1002/jbmr.1854
Woo, 2006, Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws, Ann Intern Med., 144, 753, 10.7326/0003-4819-144-10-200605160-00009
Bilezikian, 2006, Osteonecrosis of the jaw: do bisphosphonates pose a risk?, N Engl J Med., 355, 2278, 10.1056/NEJMp068157
Khosla, 2007, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res., 22, 1479, 10.1359/jbmr.0707onj
Khan, 2015, Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus, J Bone Miner Res., 30, 3, 10.1002/jbmr.2405
Bauer, 2000, Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial, Arch Intern Med., 160, 517, 10.1001/archinte.160.4.517
Lenart, 2009, Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study, Osteoporos Int., 20, 1353, 10.1007/s00198-008-0805-x
Shane, 2014, Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res., 29, 1, 10.1002/jbmr.1998
Watts, 1999, The clinical tolerability profile of alendronate, Int J Clin Pract Suppl., 101, 51
de Groen, 1996, Esophagitis associated with the use of alendronate, N Engl J Med., 335, 1016, 10.1056/NEJM199610033351403
Shane, 2010, Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res., 25, 2267, 10.1002/jbmr.253
Kim, 2011, Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort, J Bone Miner Res., 26, 993, 10.1002/jbmr.288
Sharma, 2013, Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis, Chest., 144, 1311, 10.1378/chest.13-0675
Sharma, 2014, Risk of atrial fibrillation with use of oral and intravenous bisphosphonates, Am J Cardiol., 113, 1815, 10.1016/j.amjcard.2014.03.008
Schwartz, 2010, Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial, J Bone Miner Res., 25, 976, 10.1002/jbmr.11
Black, 2015, The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res., 30, 934, 10.1002/jbmr.2442
Cosman, 2014, Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?, J Clin Endocrinol Metab., 99, 4546, 10.1210/jc.2014-1971
Adler, 2016, Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research, J Bone Miner Res., 31, 16, 10.1002/jbmr.2708
Black, 2012, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res., 27, 243, 10.1002/jbmr.1494
Compston, 2002, Combination therapy for postmenopausal osteoporosis, Clin Endocrinol., 56, 565, 10.1046/j.1365-2265.2002.01536.x
Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med., 349, 1207, 10.1056/NEJMoa031975
Cosman, 2011, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis, J Bone Miner Res., 26, 503, 10.1002/jbmr.238
Leder, 2014, Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial, J Clin Endocrinol Metab., 99, 1694, 10.1210/jc.2013-4440
Leder, 2015, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial, Lancet., 386, 1147, 10.1016/S0140-6736(15)61120-5
Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, N Engl J Med., 349, 1216, 10.1056/NEJMoa035725
Rittmaster, 2000, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate, J Clin Endocrinol Metab., 85, 2129
Diab, 2013, Postmenopausal osteoporosis, Curr Opin Endocrinol Diabetes Obes., 20, 501, 10.1097/01.med.0000436194.10599.94
Leder, 2009, Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis, J Clin Endocrinol Metab., 94, 2915, 10.1210/jc.2008-2630
Kallmes, 2009, A randomized trial of vertebroplasty for osteoporotic spinal fractures, N Engl J Med., 361, 569, 10.1056/NEJMoa0900563
Buchbinder, 2009, A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures, N Engl J Med., 361, 557, 10.1056/NEJMoa0900429
Staples, 2011, Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis, BMJ., 343, d3952, 10.1136/bmj.d3952
Kroon, 2014, Two-year results of a randomized placebo-controlled trial of vertebroplasty for acute osteoporotic vertebral fractures, J Bone Miner Res., 29, 1346, 10.1002/jbmr.2157
Blasco, 2012, Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures: a 12-month randomized follow-up, controlled trial, J Bone Miner Res., 27, 1159, 10.1002/jbmr.1564
Klazen, 2010, Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II, AJNR Am J Neuroradiol., 31, 1447, 10.3174/ajnr.A2148
Bouza, 2015, Safety of balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures in Europe: a meta-analysis of randomized controlled trials, Eur Spine J., 24, 715
Aghamirsalim, 2012, Do the hospitalized patients with osteoporotic fractures require endocrinologists’ help?, J Endocrinol Invest., 35, 992
Bell, 2014, Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review, Arch Osteoporos., 9, 167, 10.1007/s11657-013-0167-7
Radonich, 2006
Edwards, 1999, How should effectiveness of risk communication to aid patients’ decisions be judged? A review of the literature, Med Decis Making., 19, 428, 10.1177/0272989X9901900411
Lewiecki, 2011, 2011 The role of risk communication in the care of osteoporosis, Curr Osteoporos Rep., 9, 141, 10.1007/s11914-011-0056-1
Charles, 2003, Shared treatment decision making: what does it mean to physicians?, J Clin Oncol., 21, 932, 10.1200/JCO.2003.05.057
Charles, 1999, Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model, Soc Sci Med., 49, 651, 10.1016/S0277-9536(99)00145-8
Charles, 1997, Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango), Soc Sci Med., 44, 681, 10.1016/S0277-9536(96)00221-3
Lewiecki, 2010, Risk communication and shared decision making in the care of patients with osteoporosis, J Clin Densitom., 13, 335, 10.1016/j.jocd.2010.06.005
Trevena, 2006, A systematic review on communicating with patients about evidence, J Eval Clin Pract., 12, 13, 10.1111/j.1365-2753.2005.00596.x
Boudreau, 2009, Preparing medical students to become attentive listeners, Med Teach., 31, 22, 10.1080/01421590802350776
Hudson, 2011, Risk communication methods in hip fracture prevention: a randomised trial in primary care, Br J Gen Pract., 61, e469, 10.3399/bjgp11X588439
Montori, 2011, Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial, Am J Med., 124, 549, 10.1016/j.amjmed.2011.01.013
Clowes, 2004, The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial, J Clin Endocrinol Metab., 89, 1117, 10.1210/jc.2003-030501
Briot, 2009, Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience, Osteoporos Int., 20, 625, 10.1007/s00198-008-0698-8
Schilcher, 2011, Bispho-sphonate use and atypical fractures of the femoral shaft, N Engl J Med., 364, 1728, 10.1056/NEJMoa1010650
Kanis, 2001, The burden of osteoporotic fractures: a method for setting intervention thresholds, Osteoporos Int., 12, 417, 10.1007/s001980170112
2003, Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study, Pharmacoepidemiol Drug Saf., 12, 195, 10.1002/pds.822